Welcome to our dedicated page for Coya Therapeutics SEC filings (Ticker: COYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Coya Therapeutics, Inc. (NASDAQ: COYA) SEC filings page provides access to the company’s U.S. Securities and Exchange Commission disclosures, which document its status as a Nasdaq-listed clinical-stage biotechnology company and outline key corporate, financing, and clinical development events. Coya’s common stock, par value $0.0001 per share, is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Stock Market LLC under the symbol COYA, as noted in multiple Form 8-K filings.
In its recent current reports on Form 8-K, Coya has disclosed material events such as milestone payments received under a Development and License Agreement with Dr. Reddy’s Laboratories Ltd. tied to FDA acceptance of an Investigational New Drug (IND) application for COYA 302 in amyotrophic lateral sclerosis (ALS) and dosing of the first patient in the Phase 2 ALSTARS Trial. Other 8-K filings describe the submission and resubmission of the IND for COYA 302, FDA review timelines, and acceptance of a Clinical Trial Application (CTA) by Health Canada.
Filings also cover capital markets activity, including an Underwriting Agreement for an underwritten public offering of common stock and related details such as the number of shares offered, offering price, estimated gross proceeds, and issuance of warrants to a financial advisor. Additional 8-Ks report quarterly financial results via furnished press releases, as well as outcomes of the company’s annual meeting of stockholders, including director elections and auditor ratification.
On Stock Titan, Coya’s SEC filings are updated as new documents are posted to EDGAR. Users can review 8-Ks related to clinical milestones, financing transactions, and governance matters, alongside other periodic and registration statements, while AI-powered tools help summarize key points and highlight items such as trial progress, milestone payments, and changes affecting COYA shareholders.
Coya Therapeutics is offering securities on a shelf registration for up to $75,000,000 to sell common stock, preferred stock, warrants, debt securities, subscription rights and units from time to time. The company is clinical-stage, focused on therapies that enhance regulatory T cells (Tregs), with lead asset COYA 302 (a combination of low-dose IL-2 and CTLA4-Ig) and an autologous Treg program that completed Phase 1 and Phase 2a studies in ALS.
Pipeline expansion includes COYA 303, a LD IL-2 plus GLP-1RA combination. A published preclinical study reported COYA 303 increased Treg suppressive function by 42% (p < 0.001) versus single agents (15% and 20%), and reduced BAX transcripts (p < 0.01), suggesting enhanced Treg survival. The company resubmitted an IND for the planned COYA 302 Phase 2 ALS study and the FDA has delayed its initial review, indicating a decision expected no later than August 29, 2025.
Financially, Coya reported net losses of $13.4 million for the six months ended June 30, 2025, an accumulated deficit of $54.1 million, and had 16,725,081 common shares outstanding; the last reported Nasdaq sale price was $6.15 per share. The company qualifies as an emerging growth company and elected the extended transition for new accounting standards.
Coya Therapeutics held $29.8 million in cash and cash equivalents as of June 30, 2025 and reported an accumulated deficit of $54.1 million. The company recorded a net loss of $6.09 million for the three months and $13.40 million for the six months ended June 30, 2025. Collaboration revenue declined to $163,616 for the quarter and $421,500 for the six months, versus substantially higher amounts in the prior-year periods driven by upfront license recognition in 2024.
The balance sheet shows $1.372 million in deferred collaboration revenue. Under the DRL Development Agreement the company received a prior upfront payment of $7.5 million and $3.9 million in a June 2024 amendment; remaining R&D services revenue is being recognized over time. The company resubmitted an IND for COYA 302 on June 30, 2025 and disclosed the FDA told the company it cannot meet the initial review goal date but expects to provide a decision no later than August 29, 2025. Management states existing cash should fund operations for at least one year after issuance of these financial statements, and that substantial additional financing will be required thereafter.
Coya Therapeutics, Inc. filed a current report to note that it issued a press release with information about its results of operations for the fiscal quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is not deemed filed for liability purposes under the Exchange Act.
Coya Therapeutics (NASDAQ:COYA) filed a Form 8-K reporting the results of its June 26, 2025 Annual Meeting of Stockholders.
- Directors re-elected: Howard Berman, Ph.D. (5,821,649 for), Arun Swaminathan, Ph.D. (6,324,520 for), and Ann Lee, Ph.D. (5,779,312 for); broker non-votes totaled 4,096,866 shares.
- Auditor ratified: Weaver & Tidwell, L.L.P. was approved as independent registered public accounting firm for FY 2025 with 10,355,085 votes for (98.9%), 68,851 against, and 340 abstentions.
No additional proposals were presented and the filing discloses no material changes to operations, strategy, or governance.